Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NASDAQ: ALEC

Alector, Inc.

Healthcare | Biotechnology

No licensed closing price on file for ALEC. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

EPS (TTM)$-1.10

Alector, Inc. (NASDAQ: ALEC) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-20 07:14 UTC.

What Alector, Inc. does

Alector is a clinical-stage biotechnology company developing therapies for neurodegenerative diseases caused by protein misfolding, deficiency, or cellular dysfunction. The company's lead program is nivisnebart, a monoclonal antibody designed to elevate progranulin levels in the brain for Alzheimer's and Parkinson's disease, currently in a Phase 2 trial expected to complete in 2026. Alector has developed the ABC platform, a proprietary technology that delivers therapeutic molecules across the blood-brain barrier to improve treatment of central nervous system conditions.

Summarized from Alector, Inc.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Pre-revenue, development-stage company: standard profitability ratios (P/E, EV/EBITDA, ROE) do not apply yet because there are no earnings. Watch cash, cash runway, net loss, R&D spend and share dilution instead.

Key facts

Valuation
EPS (TTM)$-1.10

Revenue, margins & earnings

FY2021: net loss $36M on revenue $207M$207MFY2021FY2022: net loss $133M on revenue $134M$134MFY2022FY2023: net loss $130M on revenue $97M$97MFY2023FY2024: net loss $119M on revenue $101M$101MFY2024FY2025: net loss $143M on revenue $21M$21MFY2025
  • Net income
  • Taxes & interest
  • Operating costs
  • Net loss year
Annual revenue; bands show net, operating margins · Open in Platform →

SEC Filings

SEC EDGAR ↗
Recent Insider Activity (last 90 days)
Source: SEC EDGAR · Filed 2026-10-15
  • 2026-10-15Principal Accounting OfficerEmployee Stock Option (right to buy)Returned to company-20,000—
  • 2026-10-15Chief Executive OfficerEmployee Stock Option (right to buy)Award978,750—
  • 2026-10-15Chief Executive OfficerEmployee Stock Option (right to buy)Returned to company-520,000—
Sign in to see all transactions →
Recent 8-K Events (parsed from SEC filings)All events →
Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

Company news

View all →

Questions this page answers

What does Alector, Inc. do?

Alector is a clinical-stage biotechnology company developing therapies for neurodegenerative diseases caused by protein misfolding, deficiency, or cellular dysfunction.

When did ALEC last file with the SEC?

Alector, Inc.'s most recent SEC filing on record is a 8-K filed 2026-07-08. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-20 07:14 UTC. This page is also available as JSON at /api/data?ticker=ALEC and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for ALEC and 5,000+ tickers.

Create a free account — keep ALEC
For your agent
GET /api/data?ticker=ALEC

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt